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Abstract
Objective—To estimate the associations between neuronal homeostasis, neuroprotection, and
oxidative stress candidate gene polymorphisms and neurodevelopmental disability.
Methods—This was a nested case-control analysis of a randomized trial of magnesium sulfate
administered to women at imminent risk for early (prior to 32 weeks) preterm birth for the
prevention of death or cerebral palsy in their offspring. We evaluated 21 single nucleotide
polymorphisms (SNPs) in 17 genes associated with neuronal homeostasis, neuroprotection or
oxidative stress in umbilical cord blood. Cases were infant deaths (n=43) and children diagnosed
with cerebral palsy (n=24), mental delay (Bayley Mental Developmental Index <70; n=109) and/
or psychomotor delay (Bayley Psychomotor Developmental Index <70; n=91). Controls were
race- and gender-matched children with normal neurodevelopment. Associations between each
SNP and each outcome were assessed in logistic regression models assuming an additive genetic
pattern, conditional on maternal race and infant gender, and adjusting for study drug assignment,
gestational age at birth, and maternal education.
Results—The odds of cerebral palsy were increased more than 2.5 times for each copy of the
minor allele (A) of Vasoactive intestinal polypeptide (VIP) (rs17083008) (aOR 2.67 95% CI 1.09–
6.55; p=0.03), and 4.5 times for each copy of the minor allele (T) of N-methyl-D-aspartate
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receptor subunit 3A (GRIN3A, rs3739722) (aOR 4.67 95% CI 1.36–16.01; p=0.01).The
association between the receptor for advanced glycation endproducts (AGER, rs3134945) SNP
and mental delay was modulated by study drug allocation (p=0.02).
Conclusions—VIP and NMDA receptor subunit 3A (GRIN3A) SNPs may be associated with
cerebral palsy at age 2 in infants after preterm birth.
Introduction
Preterm delivery is a major risk factor for perinatal death and neurodevelopmental disability
(NDD), including cerebral palsy (CP), in surviving infants. (1–3) It has been hypothesized
that CP and other forms of NDD are the result of neuronal injury via inflammatory, hypoxic,
excitatory, and/or oxidative mechanisms. Seventy percent of cases are now believed to be
due to prenatal or perinatal factors, with birth asphyxia only playing a minor role in infants
born preterm. (2, 4) Antenatal exposure to magnesium sulfate before anticipated early
preterm delivery has been shown to reduce the risk of CP and motor dysfunction among
survivors. (5–7) The final clinical outcome of at-risk neonates is probably affected by post-
natal events and interactions with the postnatal environment. (1)
Genetic susceptibility may modify an individual’s risk for adverse outcomes both before and
after delivery. (1, 8) There is evidence that certain genetic polymorphisms in inflammation
pathways (e.g., cytokine polymorphisms) or thrombosis pathways (e.g., inherited
thrombophilias) may be associated with a greater risk of CP and neurodevelopmental delay.
(8, 9) There are limited data regarding the role of genetic polymorphisms in other pathways,
particularly those involved with other mechanisms of neuronal injury. (8) Therefore, our
objective was to evaluate the association between NDD at age 2 or death, and
polymorphisms in candidate genes involved in neuronal homeostasis and protection, or
oxidative stress, and to assess whether these genetic polymorphisms modulate the
neuroprotective effects of magnesium sulfate.
Patients and Methods
This was a secondary analysis and a nested case-control study of the Eunice Kennedy
Shriver National Institute of Child Health and Human Development (NICHD) Maternal-
Fetal Medicine Units Network “Randomized Clinical Trial of the Beneficial Effects of
Antenatal Magnesium Sulfate” (BEAM), in which women with singleton or twin gestations
between 24–316/7 weeks of gestation at high risk for imminent preterm birth were
randomized in a double-blind fashion to receive either magnesium sulfate infusion or
identical-appearing placebo. (5) Group assignment in the original trial was made according
to a computer-generated random sequence using the urn design, with stratification according
to clinical center and, in twin pregnancies, weeks of gestation (<28 or ≥28). (10) Further
details of the study, which was conducted at 20 institutions between December 1997 and
May 2004, are described elsewhere. (5) The primary outcome of the trial was a composite of
infant death or moderate to severe CP at the age of 2 years. Additionally, as secondary
outcomes, the trial assessed other neurodevelopmental outcomes (psychomotor and mental
delay) at age 2.
For the current analysis, we included infants who died by 1 year of corrected age or were
diagnosed with CP, mental delay or psychomotor delay at or beyond 2 years of corrected
age. DNA and two-year data on neurological outcomes were required for inclusion. Mental
and psychomotor delay were defined by scores of <70 at age 2 years using the Bayley Scales
of Infant Development II mental and psychomotor developmental indices (MDI and PDI,
respectively) administered by a centrally certified psychologist or psychometrist. CP was
determined by a centrally certified pediatrician or pediatric neurologist according to pre-
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specified criteria of gross motor delay, abnormality in muscle tone or movement, or reflexes.
(5) The control group consisted of infants who survived until 2 years of age with normal
neurodevelopment (Bayley MDI and PDI ≥ 85) and without CP, periventricular
leukomalacia or intraventricular hemorrhage grade III or IV. We excluded cases of fetal
demise and neonates with major congenital malformations or genetic syndromes. Randomly
selected controls were matched to cases for ethnicity/race and infant gender, in order to
minimize the chance of misidentifying a race or gender-based genotype as one associated
with the outcome of interest. Controls were matched in a ratio of 4:1 to cases of CP, 2:1 to
cases of CP or death, and 1:1 to cases of mental and psychomotor delay. This study was
deemed exempt from institutional review board review since the data and samples were de-
identified before the analysis was performed.
DNA extraction and SNP selection
DNA extraction, amplification and genotyping were done at Taueret Laboratories (Salt Lake
City, Utah). Researchers and laboratory personnel were blinded to the case/control status of
the biologic samples. DNA was extracted from umbilical cord serum that had been collected
at the time of delivery using the PureGene DNA Purification System (Qiagen, Valencia,
CA), per the manufacturer’s protocols and as previously described, and then amplified for
better yield. (9) Serum samples were the only biologic material available for analysis. Due
to DNA degradation and subsequent variation in size of PCR products, DNA extracted from
serum is often of poorer quality compared to DNA extracted from whole blood. This can
result in a larger number of missing genotype values when evaluating several SNPs, which
can result in discrepant performance among SNP assays. We therefore, excluded children
whose samples either failed to genotype or had >30% of their genotype results missing
(n=47; 23 cases and 24 controls), and then excluded their corresponding case/control to
maintain the matching design. We also randomly selected one twin from each pair of
included twins (n=6) in order to avoid including related individuals in the analysis. Triplets
and higher order multiple gestations were excluded from the primary trial. We selected 21
SNPs in 17 genes associated with oxidative stress and neuronal homeostasis and
neuroprotection, based on the available literature and hypothesized causal pathways. (11–
26) The SNPs that were included in our custom multiplex assay are shown in Table 1. SNP
analysis was performed using the Taqman Single Nucleotide Polymorphism Allele
Discrimination Assay for sample genotyping (Applied Biosystems, Inc., Foster City, CA).
Predesigned TaqMan assays were used for genotyping, and genotypes were determined
using Applied Biosystems automated Taqman genotyping software, SDS v2.1.
Statistical Analysis
Demographic characteristics between cases with and without DNA samples available were
compared using Chi-square, Fisher exact, or Wilcoxon Rank Sum test for maternal
characteristics, and GEE (generalized estimating equations) for neonatal characteristics, in
order to account for the correlation between siblings. (27) Demographic characteristics
between cases and controls were compared using Chi-square, Fisher exact, or Wilcoxon
Rank Sum test. Outcomes evaluated were CP, the combined outcome of CP or death, mental
delay, and psychomotor delay. The combination of CP or death is necessary since CP and
death are competing outcomes: the former can’t be assessed when the later occurs before a
reliable diagnosis of CP can be made. Each SNP was tested for Hardy Weinberg equilibrium
in the cases group (as controls were matched to cases in this study). Logistic regression
modeling was used to analyze the association between each SNP and neonatal outcomes
accounting for demographic and clinical variables significantly different between cases and
controls or known a priori to be associated with neurodevelopmental outcomes. This
included maternal education, which is associated with the results of the Bayley Scales of
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Infant Development (the source of our measure of psychomotor and mental delay),
gestational age (GA) at delivery, which is associated with the various neurodevelopmental
outcomes, and magnesium sulfate which has been shown to be associated with a decrease in
CP. For each outcome-SNP combination, we first checked the interaction effect between the
SNP and treatment assignment. If the interaction term was not significant, then we removed
it from the model and focused on the SNP effect only. Genotypes were included as
covariates in the regression model which assumed an additive genetic pattern. The additive
genetic model assumes that each polymorphism confers additional risk and that having 2
copies of the minor allele has twice the effect of having 1 copy, and has been preferred for
its robustness among the other genetic models. All the models were based on the logistic
regression conditional on maternal race (African American, Caucasian or Hispanic) and
neonatal gender (male or female). Because this was an exploratory study, no power
calculation was conducted, and no adjustments were made for multiple comparisons. A two-
sided P-value of less than 0.05 was considered to indicate statistical significance. Statistical
analyses were performed using SAS statistical software (SAS Institute, Inc, Cary, NC).
The primary data collection was approved by the Institutional Review Boards of the
Biostatistical Coordinating Center and the clinical sites at which patients were recruited, and
all women provided written informed consent.
Results
The original trial (BEAM) included 2,444 infants, of whom 2,260 infants had long-term
neurodevelopmental outcomes available. Out of those, 668 infants were diagnosed with CP,
mental or psychomotor delay, or died; and satisfied our “cases” definition. However, out of
those 668 infant “cases”, only 231 had DNA available to be analyzed. These were then
matched to 231 infant “controls” by maternal ethnicity/race and infant gender. After
excluding infant samples that failed to genotype or had >30% of their genotype missing
(n=47; 23 cases and 24 controls), and after randomly selecting one twin from each pair (n=6;
5 cases and 1 control), the cohort remaining for analysis included 409 infants (203 cases and
206 controls). (Figure 1)
Compared with the 425 infant “cases” from the parent cohort who satisfied the inclusion
criteria but had no available DNA, the 203 infant “cases” with DNA samples available for
testing were more likely to be born singleton and at a more advanced gestational age. (Table
2)
For this analysis, there were 43 infants who died, 24 children with CP, 109 with mental
delay and 91 with psychomotor delay. There were eight children with CP and mental delay,
14 with CP and psychomotor delay, and 48 with mental and psychomotor delay. The
maternal and neonatal characteristics of all cases and controls are summarized in Table 3.
Compared with controls, cases were born at an earlier GA. Those with mental delay were
born to mothers with less education than the matched controls, and those with CP were less
likely to be from singleton gestations. There were no differences in ethnicity, study drug
assignment, chorioamnionitis, or infant gender between cases and controls (Table 3).
Out of 21 SNPs chosen, the assay for one SNP (NRG1, rs35753505) failed manufacturing,
and another SNP (GRIN3B C/T, rs480739) failed to genotype in >30% of the samples, and
these were excluded from further analysis. In the remainder, genotype determination was
overall successful in 94% of samples (range 88 – 99 % for individual SNPs). Four SNPs
(vasoactive intestinal polypeptide [VIP] rs17083008, GPX1 rs1800668, RELN rs362691,
and VPAC2 rs885861) were in Hardy Weinberg disequilibrium (p<0.01).
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Two SNPs (VIP rs17083008 and GRIN3A rs3739722) were associated with CP. The
genotype frequency of these SNPs in cases and controls are summarized in Table 4. The VIP
(A) allele and GRIN3A (T) allele were associated with increased risk of CP (adjusted OR
(aOR) 2.67, 95% CI 1.09–6.55; p=0.03, and 4.67, 95% CI 1.36–16.01; p=0.01) respectively.
We tried to add an additional interaction term but observed no significant interaction with
magnesium sulfate treatment (p=0.86 and 0.89, respectively). The AGER rs3134945 SNP
was differentially associated with mental delay, depending on exposure to magnesium
sulfate. For this SNP there was an interaction with magnesium sulfate treatment (p=0.02),
therefore we analyzed the association in the placebo and magnesium sulfate treated groups
separately. Despite this significant interaction, however, there was no significant association
between the minor allele (A) and mental delay either in the placebo group (aOR 0.51, 95%
CI 0.24 – 1.07; p=0.08) or in the magnesium sulfate group (aOR 1.83, 95% CI 0.89 – 3.73;
p=0.10). (Figure 2)
Discussion
In this study, we found that polymorphism in the vasoactive intestinal polypeptide gene
(VIP, rs17083008) and GRIN3A gene (which encodes the N-methyl-D-aspartate receptor
3A subunit (NR3A) were associated with an increased risk of cerebral palsy. The AGER,
which encodes the receptor for advanced glycation endproducts (RAGE), rs3134945 SNP
was differentially associated with mental delay, depending on exposure to magnesium
sulfate.
VIP is an endogenous neuromodulator and neuroprotective peptide in the CNS. (28) Its
neuroprotective role against ischemic and glutamate induced excitatory brain injury is
mediated by VIP receptors (VPAC 1 and 2 subtypes). (14, 15) VIP stimulates astrocytes to
produce neuroprotective agents in particular the potent activity-dependent neurotrophic
factor (ADNF) and activity-dependent neuroprotective protein (ADNP), and inhibits the
production of inflammatory cytokines by activated microglia. (28) Functional genetic
polymorphisms in both VIP and VPAC2 genes have been described. (14–16) In particular,
the VIP (rs17083008), located in the promoter/regulatory region, is predicted to have a
potential functional role since it alters a transcription factor-binding site, may be associated
with lower VIP levels, and is thought to be associated with bipolar and other
neurobehavioral disorders. (16)
N-methyl-D-aspartate (NMDA) receptors are tetrameric glutamate/calcium ion channels
expressed on astrocytes and oligodendrocytes, and essential in excitatory synaptic
transmission in the CNS. (29, 30) It has been postulated that NMDA receptors play an
essential role in the pathogenesis of CP. (31, 32) Briefly, in the setting of hypoxic injury,
cells shift to anaerobic metabolism, increase lactate and glutamate production. The latter
then binds and coactivates NMDA receptors, leading to influx of Ca++ intracellularly, lipid
peroxidation, free radical production and cell death/injury. Magnesium is a non-competitive
inhibitor of these NMDA receptors blocking the influx of Ca++ into the cells and thus
protects against cell damage/death. (31, 32) There are 3 major subunits of the NMDA
tetramer (NR1, NR2 and NR3). (29) NR3A is one of the two types of the NR3 subunit and
has been shown to be highly expressed in oligodendrocytes where glutamate toxicity leads
to damage in the myelin sheath. Its expression in the dendirtic spines implies a role in
synaptic stability and neuronal activity. (29, 30) The NMDA NR3A are abundantly
expressed on the myelin sheath, and are only weakly blocked by extracellular Mg2+, making
them more vulnerable to glutamate toxicity damage. (29) The currently described SNP is an
exonic polymorphism at position 3723 in the GRIN3A gene that encodes the NR3A, and has
been found to be associated with Alzheimer disease. (22)
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Last, animal and human studies suggest that inflammation and oxidative stress in the
developing fetal brain are associated with brain injury and subsequent development of CP
(31–33). The host’s defense to an inflammatory insult involves a group of intracellular
proteins called damage-associated molecular pattern molecules or DAMPs, which when
released into the extracellular milieu after an insult, activate the receptor for advanced
glycation end-products (RAGE) (33). This will then lead to activation of multiple cellular
signaling cascades mediated by NFκB, and amplification of the inflammatory and oxidative
stress signaling, potentiating and accelerating cellular damage and dysfunction. (33). We
have previously shown in a nested case control study from the same cohort that a naturally
occurring soluble truncated variant of RAGE (sRAGE) was decreased in the cord blood of
neonates who ultimately died after preterm birth (34), indicating a possible role of RAGE
activation in neurodevelopmental disability or death. In this study, we have found that the
AGER SNP (rs3134945), which is located in the 3′ untranslated region of the AGER gene
and its function is still unknown, was differentially associated with mental delay, depending
on exposure to magnesium sulfate. However, despite this significant interaction, there was
no significant association between the minor allele (A) and mental delay in either group.
The major strength of this study is that it was nested in a multicenter trial where the
outcomes were clearly defined and the data and specimen carefully collected in a standard
fashion. Umbilical cord serum samples were the only biologic material available for
analysis. Because of the poorer quality of DNA extracted from serum, we eliminated
individual serum samples and specific SNP assays that genotyped poorly compared to other
samples and SNPs. We then excluded their corresponding case/control to maintain the
matching the status. We used an elimination cut-off of >30% missing results for serum
samples and SNP assays. Given the relatively small number of candidate SNPs, a more
rigorous cut-off would have resulted in exclusion of a large number of high-quality serum
samples with as few as one missing genotype. After excluding serum samples that entirely
failed to genotype (n=26) and samples with >30% of genotypes missing (n=21), the average
individual sample genotype call rate over the 19 markers was 98%. Using the same
exclusions, the 19 SNPs had an average genotype call rate of 97%. This elimination method
for both individual serum samples and specific SNP assays resulted in a robust genetic
analysis without bias towards inclusion of erroneous genotypes. Our study was limited by
the sample size which did not permit us to evaluate gene-environment interactions on
subsequent survival and neurodevelopmental outcomes.
Table 2 compares infant “cases” with or without DNA available, and it was intended to see
whether the remaining sample is representative of the entire study cohort. We speculated
that the difference in GA and twin gestations seen between infants who had DNA samples
available, compared with those who did not, may be related to difficulty in obtaining
sufficient cord blood from the smallest neonates and in multiple gestations. These
differences are not a significant source of systematic selection bias for the case-control
secondary analysis reported, although they may limit ability to extrapolate to the primary
study population. We also performed an analysis with a covariate for twin vs. singleton
gestation, and all results have remained similar. In addition, data were not available to assess
the influence of other variables that may be associated with adverse neurodevelopmental
outcomes such as histologic chorioamionitis, funisitis, and acidosis at birth. As this was an
exploratory analysis, no corrections were made for multiple comparisons and all
associations were reported despite the possibility that some associations may be statistically
significant but not clinically meaningful, and some statistically significant associations may
have been due to chance (type I error). Our findings need to be confirmed in other cohorts.
The possibility of false negatives cannot be excluded as well. Given the limited number of
SNPs analyzed, the genetic variation within the selected genes was not fully captured.
Costantine et al. Page 6













In conclusion, survival and risk of adverse neurodevelopmental outcomes are determined by
complex interactions between genes and the intrauterine and postnatal environment. VIP and
NMDA receptor subunit 3A (GRIN3A) SNPs may be associated with cerebral palsy at age 2
in infants after preterm birth. This work supports the potential role of genetic predisposition
to death and neurodevelopmental disability in preterm infants, and suggests that genetic
predisposition may alter responses to antenatal magnesium sulfate treatment and risk of
death and adverse neurodevelopmental outcomes. Knowledge of individual fetal genetic risk
may ultimately lead to new preventative and therapeutic strategies that optimize
neurodevelopment after preterm birth.
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Selection of cases and controls. The control group consisted of infants who survived until 2
years of age with normal neurodevelopment (Bayley Mental and Psychomotor
Developmental Indices 85 or greater and without cerebral palsy, periventricular
leukomalacia, or intraventricular hemorrhage grade 3 or 4).
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Genotype frequencies and adjusted odds ratios for advanced glycation endproducts specific
receptor (AGER; rs3134945) polymorphism and association with mental delay. The Y axis
is the percentage of various genotypes. aOR, adjusted odds ratio; CI, confidence interval.
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Table 1
Single Nucleotide Polymorphisms of Selected Genes Included in the Analysis
Gene Pathway Symbol Polymorphism RS Number
N-methyl-D-aspartate receptor 2B subunit gene NHP GRIN2B −200 (T/G) rs1019385
N-methyl-D-aspartate receptor 3B subunit gene NHP
GRIN3B 1730 (C/T) rs2240158
GRIN3B 1210 (C/T) rs4807399
N-methyl-D-aspartate receptor 3A subunit gene NHP GRIN3A 3723 (G/A) rs3739722
Vasoactive intestinal peptide NHP VIP (A/G) rs17083008
Vasoactive intestinal peptide receptor 2 NHP VPAC2
393 (C/A) rs2098349
1760 (C/T) rs885861




Neuregulin-1 NHP NRG1 C/T rs35753505
Transient receptor potential melastatin 7 NHP TRPM7 Ile1482Thr rs8042919




Receptor for advanced glycation endproducts OX AGER 64 (C/A) rs3134945
Toll like receptor 4 OX TLR4 Asp299Gly rs4986790
Kalirin NHP KALRN −9759 (C/T) rs11712039
Inducible nitric oxide synthase OX NOS2 −231 (C/T) rs1137933
Glutathione peroxidase 1 OX GPX1 35 (C/T) rs1800668
Superoxide dismutase 2 OX SOD2 24 (T/C) rs4880
NHP, neuronal homeostasis and protection pathway; OX, oxidative stress pathway.
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Table 2
Characteristics of Cases With and Without DNA Samples Available
Cases*
n=628
DNA Samples† n=203 No DNA Samples n=425 P
Ethnicity 0.42
 African American 91 (44.8) 214 (50.4)
 Caucasian 68 (33.5) 131 (30.8)
 Hispanic 44 (21.7) 80 (18.8)
Maternal education (years) 12 [10,12] 12 [11,13] 0.10
Allocated to magnesium sulfate 97 (47.8) 196 (46.1) 0.70
Gestational age at birth (weeks) 29.6 [26.6, 31.6] 27.4 [25.4, 29.9] <0.001
Singleton 183 (90.1) 352 (82.8) 0.02
Male gender‡ 130 (64.0) 264 (56.8) 0.08
*
Cases were infants who died by age 1 or developed cerebral palsy, mental or psychomotor delay by age 2. Controls were infants who survived
until 2 years of age with normal neurodevelopment and without cerebral palsy.
†
 The sample size was based on the maternal patients with eligible neonatal outcomes.
‡
 Generalized estimating equation was used to adjusted for twins in the neonatal patients (DNA samples n=203 and no DNA samples n=465).
Data are median [interquartile range] or n (%) unless otherwise specified.
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